DN Venture Partners has been conducting business missions to Asia since 2005, helping top executives and investors from biotech industry gain a broad perspective and in-depth understanding of the sector in Asia. More importantly, we have been helping these organisations establish critical links to the regional biotech industry.
China
Conference on Clinical Trials Asia Summit 2010
Submitted by bharatbookseo on Sat, 10/07/2010 - 07:41Clinical Trials Asia Summit
2010
19, 20, August 2010, Taj Residency (M.G. Road), Bangalore, India
"Improving clinical practice & trial success rates with improved technologies,
strategies & alliance management"
ChinaBio® Partnering Forum 2010
Submitted by EBD Group on Mon, 21/06/2010 - 18:45June 23–24, 2010 • Suzhou, China
Conference on 9th Annual Pricing and Reimbursement(
Submitted by bharatbookseo on Sat, 19/06/2010 - 10:38- Adam Barak
- Africa
- Alexion Pharmaceuticals
- Andrea Rappagliosi
- Anne-Toni Rodgers
- Asia
- Asia’s Emerging Evidence Networks
- Astellas Pharma
- Baxter World Trade
- biopharmaceutical
- Brazil
- Brian Smith
- British Institute
- British Institute of International
- Brussels
- BsG Conference Centre
- Canada
- China
- Cyrus Chowdhury
- Dermot Glynn
- Donald Macarthur
- Europe
- Europe Economics
- France
- Germany
- GlaxoSmithKline
- Health Economics
- healthcare
- India
- International Trade
- Italy
- Janice Haigh
- Japan
- Jorge Mestre-Ferrandiz
- Journal
- London
- Luis Gonzalez Vaque
- Market Policy
- Mexico
- Middle East
- Mondher Toumi
- Nicole Mather
- Parallel Trade
- Person Career
- Person Education
- pharmaceutical
- Pricing
- Razmic Gregorian
- Russia
- Sarah Pitluck
- SIMON
- Simon-Kucher
- Spain
- Taiwan
- Thailand
- Trevor Leighton
- Turkey
- United BioSource Corporation
- United Kingdom
- University of Lyon
Conference on 9th Annual Pricing and Reimbursement
Delivering practical solutions and initiating winning strategies to streamline
your P&R decisions
27th - 29th September 2010, BSG Conference Centre, London, UK
Key Speakers
Dr. Jorge Mestre-Ferrandiz, Senior Economist, Office of Health Economics,
Now that Abbot bought Piramal...what's next for Pfizer???
Submitted by Anonymous on Fri, 21/05/2010 - 18:04PFIZER has deal with Strides Arcolab....Aurobindo and Claris Life Sciences....
Rumors is for Laboratorio Teuto Brasileiro in Brasil.....but Pfizer may be looking for generic in india or China also....
any idea who???
2nd DIA China Annual Meeting
Submitted by mkeller on Tue, 09/03/2010 - 14:56Date(s) And Time(s):
May 16 2010 8:00AM - May 19 2010 5:00PM
Overview:
China’s drug innovation and development are moving ahead rapidly. A local, as well as global, perspective will help all players involved to exchange critical information for research and strategic positioning in an increasingly complex regulatory landscape.
Where is Beckman Coulter going?
Submitted by Anonymous on Wed, 23/09/2009 - 00:59It's no secret that Beckman Coulter has terminated the employment of many long term, hard working employees across all areas of the company. Many of those functions have been outsourced to other firms. Some functions like accounts payable or small subassembly manufacturing can be outsourced fairly easily.
Wyeth Sites to survive?
Submitted by Anonymous on Sun, 23/08/2009 - 21:39Obviously Pearl will survive since Prevnar is the bread and butter right now. Any other ideas about Grange, Andover and Cambridge?
Invitrogen = China peptides
Submitted by Anonymous on Mon, 17/08/2009 - 15:29Just received an email promotion from GL Biochem stating that they have been supplying Invitrogen with peptides since 2008.
Sad to say Invitrogen has joined other companies who resell China peptides: Biomatik, CPC, Chempep, Genescript, Peptide 2.0, and SynBioSci. Just to name a few.
>Now,Invitrogene company is one of our stable customers.
VWR Layoffs not helping company. Company still bleeding
Submitted by Anonymous on Thu, 15/01/2009 - 00:31The latest round of job cuts at VWR are not helping the oompany as the company continues to see revenue decreases, margin losses and customers leaving. Management is trying to "Save" their way to profitability by cutting cost, mainly people. It will not work it appears.